Ligand Pharmaceuticals will hold an Investor Day in New York on December 9, 2025, detailing company strategies and financial outlook.
Quiver AI Summary
Ligand Pharmaceuticals Incorporated announced it will hold an Investor Day on December 9, 2025, at the Harvard Club in New York City, featuring presentations from its senior management on the company's strategy, investment activities, royalty portfolio, and long-term financial outlook. The event will be accessible via a live webcast on Ligand's Investor Relations website. Ligand is a biopharmaceutical company focused on supporting the development of high-value medicines through financing, licensing, and a diversified revenue model. The company collaborates with major pharmaceutical companies and operates two key technology platforms, Captisol® and NITRICIL™, to optimize drug formulations. More information is available on Ligand's website and through their investor relations communications.
Potential Positives
- Ligand Pharmaceuticals is hosting an Investor Day, providing a platform for transparency and engagement with investors, which can enhance investor relations and confidence in the company.
- The event will showcase presentations from senior management, highlighting the company's strategy and long-term financial outlook, indicating a commitment to clear communication about its business direction.
- The use of a live webcast for the event increases accessibility for investors, allowing a broader audience to participate and engage with the company's updates and insights.
- Ligand's established partnerships with leading pharmaceutical companies enhance its credibility and demonstrate strong collaborative potential within the biopharmaceutical industry.
Potential Negatives
- The press release does not provide any specific information about current financial performance or recent achievements, which may raise concerns among investors about the company's transparency regarding its current status.
- The invitation to an Investor Day could imply that the company is under pressure to communicate its strategy and outlook, potentially indicating a lack of confidence in its ongoing performance.
- Details about the company's revenue-generating ventures and partnerships are vague, which could lead to skepticism about the sustainability of its business model.
FAQ
What is the date and time of Ligand Pharmaceuticals' Investor Day?
Ligand Pharmaceuticals' Investor Day will be held on December 9, 2025, at 10 a.m. Eastern Time.
Where will the Investor Day event take place?
The Investor Day event will be hosted at the Harvard Club in New York City.
Will there be a live webcast for the Investor Day?
Yes, a live webcast of the Investor Day will be available on Ligand's Investor Relations website.
What topics will be covered during the Investor Day?
The event will cover Ligand's strategy, investment activity, royalty portfolio, and long-term financial outlook.
How can investors get more information about the event?
More information, including a detailed agenda and dial-in information, will be provided closer to the event date.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LGND Insider Trading Activity
$LGND insiders have traded $LGND stock on the open market 8 times in the past 6 months. Of those trades, 5 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $LGND stock by insiders over the last 6 months:
- TODD C DAVIS (Chief Executive Officer) has made 3 purchases buying 9,510 shares for an estimated $1,000,456 and 0 sales.
- OCTAVIO ESPINOZA (Chief Financial Officer) has made 2 purchases buying 1,500 shares for an estimated $156,090 and 2 sales selling 7,104 shares for an estimated $819,998.
- ANDREW REARDON (CLO & Secretary) sold 1,000 shares for an estimated $104,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LGND Hedge Fund Activity
We have seen 129 institutional investors add shares of $LGND stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 205,689 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $22,039,576
- JACOBS LEVY EQUITY MANAGEMENT, INC added 157,181 shares (+inf%) to their portfolio in Q1 2025, for an estimated $16,526,010
- RANGER INVESTMENT MANAGEMENT, L.P. added 107,885 shares (+131.2%) to their portfolio in Q1 2025, for an estimated $11,343,028
- ABRDN PLC removed 72,509 shares (-29.1%) from their portfolio in Q4 2024, for an estimated $7,769,339
- BAIRD FINANCIAL GROUP, INC. removed 65,570 shares (-84.9%) from their portfolio in Q1 2025, for an estimated $6,894,029
- PRUDENTIAL FINANCIAL INC removed 62,040 shares (-60.2%) from their portfolio in Q1 2025, for an estimated $6,522,885
- ENVESTNET ASSET MANAGEMENT INC removed 60,587 shares (-69.5%) from their portfolio in Q1 2025, for an estimated $6,370,117
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern Time at the Harvard Club.
The event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand’s Investor Relations website at investor.ligand.com . A detailed agenda, including dial-in information, will be provided closer to the event.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit
www.ligand.com
. Follow Ligand on
X
and
LinkedIn
.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
[email protected]
(858) 550-7761
Media:
Kellie Walsh
[email protected]
(914) 315-6072
